Tigatuzumab, developed at UAB with Daiichi-Sankyo, targets aggressive, hard-to-treat tumors that make up 25 percent of all breast cancers

Published in Focus on Patient Care

Sleep deprivation, stress and a confused circadian clock can be a lethal combination  

Page 5 of 5
Back to Top